Access to precision cancer medicine relies on correctly isolating cancer cells from a biopsy, a difficult task with existing methods. SynderBio has developed a patented cell separation technology, unlocking the potential of genomic sequencing for cancer diagnostics, single-cell sequencing, and broader life science applications. Genomic markers can define precision treatments in cancer, but difficulties in processing biopsy samples limit routine use. In the US alone, 78,000 cancer patients miss out on precision treatments and drug companies lose $8.3B annually due to the inadequacy of current biopsy preparation tools. SynderBio will fix this problem, selling a benchtop instrument/disposable kit by 2022 and achieving >$200M in revenue by 2026.